Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Genetic Counseling
Published in: Journal of Genetic Counseling 1/2011

01-02-2011 | Professional Issues

Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review

Authors: Scott M. Weissman, Cecelia Bellcross, Christina Chimera Bittner, Mary E. Freivogel, Joy Larsen Haidle, Pardeep Kaurah, Anna Leininger, Selvi Palaniappan, Kelle Steenblock, Thuy M. Vu, Molly S. Daniels

Published in: Journal of Genetic Counseling | Issue 1/2011

Login to get access

Abstract

Lynch syndrome is the most common hereditary colorectal cancer syndrome and the most common cause of hereditary endometrial cancer. Identifying and evaluating families for Lynch syndrome is increasing in complexity due to the recognition that: family history-based clinical criteria lack sensitivity and specificity; genetic testing for Lynch syndrome continues to evolve as understanding of the molecular mechanisms underlying it evolves; and the Lynch syndrome phenotype encompasses multiple organ systems and demonstrates overlap with other hereditary cancer syndromes. This document is a summary of considerations when evaluating individuals and families for Lynch syndrome, including information on cancer risks, diagnostic criteria, tumor and genetic testing strategies, and the management of individuals with this condition.
Literature
Aaltonen, L. A., Salovaara, R., Kristo, P., Canzian, F., Hemminki, A., Peltomaki, P., et al. (1998). Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. The New England Journal of Medicine, 338(21), 1481–1487.PubMed
Aarnio, M., Salovaara, R., Aaltonen, L. A., Mecklin, J. P., & Jarvinen, H. J. (1997). Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. International Journal of Cancer, 74, 551–555.
Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, A., et al. (1999). Cancer risk in mutation carriers of DNA-mismatch-repair genes. International Journal of Cancer, 81(2), 214–218.
Abbas, O., & Mahalingam, M. (2009). Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. Journal of Cutaneous Pathology, 36(6), 613–619.PubMed
Backes, F. J., Leon, M. E., Ivanov, I., Suarez, A., Frankel, W. L., Hampel, H., et al. (2009). Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 114(3), 486–490.PubMed
Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, E. B., et al. (2009). Risks of Lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193–201.PubMed
Balmana, J., Stockwell, D. H., Steyerberg, E. W., Stoffel, E. M., Deffenbaugh, A. M., Reid, J. E., et al. (2006). Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA, 296(12), 1469–1478.PubMed
Bandipalliam, P. (2005). Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer, 4(4), 323–333.PubMed
Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751–2763.PubMed
Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242.PubMed
Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et al. (2009). Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141–149.PubMed
Berends, M. J., Hollema, H., Wu, Y., van Der Sluis, T., Mensink, R. G., ten Hoor, K. A., et al. (2001). MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. International Journal of Cancer, 92(3), 398–403.
Berends, M. J., Wu, Y., Sijmons, R. H., Mensink, R. G., van der Sluis, T., Hordijk-Hos, J. M., et al. (2002). Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. American Journal of Human Genetics, 70(1), 26–37.PubMed
Boland, C. R. (2005). Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer, 4(3), 211–218.PubMed
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research, 58(22), 5248–5257.PubMed
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Moslein, G., Olschwang, S., et al. (2008). Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. The New England Journal of Medicine, 359(24), 2567–2578.PubMed
Burn, J., Gerdes, A. M., Mecklin, J. P., Macrae, F., Moeslein, G., Olschwang, S., et al. (2009). Aspirin prevents cancer in Lynch Syndrome: results of long term follow-up in the CAPP2 trial. (program #113). Presented at the 59th Annual Meeting of the American Society of Human Genetics, October 23, 2009, Honolulu, Hawaii. Available at http://​www.​ashg.​org/​2009meeting/​abstracts/​fulltext/​.
Casey, G., Lindor, N. M., Papadopoulos, N., Thibodeau, S. N., Moskow, J., Steelman, S., et al. (2005). Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA, 293(7), 799–809.PubMed
Catto, J. W. F., Azzouzi, A. R., Amira, N., Rehman, I., Feeley, K. M., Cross, S. S., et al. (2003). Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene, 22, 8699–8706.PubMed
Catto, J. W., Azzouzi, A. R., Rehman, I., Feeley, K. M., Cross, S. S., Amira, N., et al. (2005). Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. Journal of Clinical Oncology, 23(13), 2903–2910.PubMed
Chao, E. C., Velasquez, J. L., Witherspoon, M. S., Rozek, L. S., Peel, D., Ng, P., et al. (2008). Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Human Mutation, 29(6), 852–860.PubMed
Chen, S., Wang, W., Lee, S., Nafa, K., Lee, J., Romans, K., et al. (2006). Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA, 296(12), 1479–1487.PubMed
Chen, S., Euhus, D., & Parmigiani, G. (2007). Quantitative models for predicting mutations in Lynch syndrome genes. Current Colorectal Cancer Reports, 3(4), 206–211.
Choi, M. Y., Lauwers, G. Y., Hur, C., Willett, C. G., & Chung, D. C. (2007). Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. International Journal of Radiation Oncology, Biology, Physics, 68(5), 1584.PubMed
De Jong, A. E., Morreau, H., Van Puijenbroek, M., Eilers, P. H., Wijnen, J., Nagengast, F. M., et al. (2004a). The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology, 126(1), 42–48.PubMed
De Jong, A. E., van Puijenbroek, M., Hendriks, Y., Tops, C., Wijnen, J., Ausems, M. G., et al. (2004b). Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clinical Cancer Research, 10(3), 972–980.PubMed
De Jong, A. E., Hendriks, Y. M. C., Kleibeuker, J. H., de Boer, S. Y., Cats, A., Griffioen, G., et al. (2006). Decrease in mortality in lynch syndrome families because of surveillance. Gastroenterology, 130(3), 665–671.PubMed
Dijkhuizen, F. P., Mol, B. W., Brolmann, H. A., & Heintz, A. P. (2000). The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer, 89(8), 1765–1772.PubMed
Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., et al. (2004). BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. Journal of Medical Genetics, 41(9), 664–668.PubMed
Dove-Edwin, I., Boks, D., Goff, S., Kenter, G. G., Carpenter, R., Vasen, H. F., et al. (2002). The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer, 94(6), 1708–1712.PubMed
Dunlop, M. G., Farrington, S. M., Carothers, A. D., Wyllie, A. H., Sharp, L., Burn, J., et al. (1997). Cancer risk associated with germline DNA mismatch repair gene mutations. Human Molecular Genetics, 6(1), 105–110.PubMed
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009). Recommendations from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.
Fenoglio-Preiser, C., Carneiro, F., Correa, P., Guilford, P., Lambert, R., Megraud, F., et al. (2000). Gastric carcinoma. In S. R. Hamilton & L. A. Aaltonen (Eds.), Pathology and genetics of tumours of the digestive system (pp. 39–52). Lyon: IARC.
Gazzoli, I., Loda, M., Garber, J., Syngal, S., & Kolodner, R. D. (2002). A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Research, 62(14), 3925–3928.PubMed
Geisler, J. P., Goodheart, M. J., Sood, A. K., Holmes, R. J., Hatterman-Zogg, M. A., & Buller, R. E. (2003). Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer, 98(10), 2199–2206.PubMed
Giardiello, F. M., Brensinger, J. D., & Petersen, G. M. (2001). AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology, 121(1), 198–213.PubMed
Goodfellow, P. J., Buttin, B. M., Herzog, T. J., Rader, J. S., Gibb, R. K., Swisher, E., et al. (2003). Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proceedings of the National Academy of Sciences of the United States of America, 100(10), 5908–5913.PubMed
Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., et al. (1995). The molecular basis of Turcot’s syndrome. The New England Journal of Medicine, 332(13), 839–847.PubMed
Hampel, H. (2009). Genetic testing for hereditary colon cancer. Surgical Oncology Clinics of North America, 18, 687–703.PubMed
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860.PubMed
Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J. P., et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology, 129(2), 415–421.PubMed
Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810–7817.PubMed
Hampel, H., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., Comeras, I., et al. (2007). Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 67(19), 9603.PubMed
Hartmann, A., Zanardo, L., Bocker-Edmonston, T., Blaszyk, H., Dietmaier, W., Stoehr, R., et al. (2002). Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Research, 62, 6796–6802.PubMed
Hayden, J. D., Martin, I. G., Cawkwell, L., & Quirke, P. (1998). The role of microsatellite instability in gastric carcinoma. Gut, 42, 300–303.PubMed
Heinimann, K., Scott, R. J., Buerstedde, J. M., Weber, W., Siebold, K., Attenhofer, M., et al. (1999). Influence of selection criteria on mutation detection in patients with hereditary nonpolyposis colorectal cancer. Cancer, 85(12), 2512–2518.PubMed
Hendriks, Y. M., Wagner, A., Morreau, H., Menko, F., Stormorken, A., Quehenberger, F., et al. (2004). Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology, 127(1), 17–25.PubMed
Hitchins, M. P., & Ward, R. L. (2009). Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. Journal of Medical Genetics, 46(12), 793–802.PubMed
Hitchins, M. P., Wong, J. J., Suthers, G., Suter, C. M., Martin, D. I., Hawkins, N. J., et al. (2007). Inheritance of a cancer-associated MLH1 germ-line epimutation. The New England Journal of Medicine, 356(7), 697–705.PubMed
Horner, M. J., Ries, L. A. G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., et al. (Eds.). (2009). SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2006/​, based on November 2008 SEER data submission, posted to the SEER web site.
Iino, H., Simms, L., Young, J., Arnold, J., Winship, I. M., Webb, S. I., et al. (2000). DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut, 47(1), 37–42.PubMed
Jarvinen, H. J., Aarnio, M., Mustonen, H., Aktan-Collan, K., Aaltonen, L. A., Peltomaki, P., et al. (2000). Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology, 118(5), 829–834.PubMed
Jass, J. R. (2006). Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World Journal of Gastroenterology, 12(31), 4943–4950.PubMed
Jass, J. R., & Stewart, S. M. (1992). Evolution of hereditary non-polyposis colorectal cancer. Gut, 33(6), 783–786.PubMed
Jenkins, M. A., Hayashi, S., O’Shea, A. M., Burgart, L. J., Smyrk, T. C., Shimizu, D., et al. (2007). Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology, 133(1), 48–56.PubMed
Jones, S., Chen, W. D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal, T., et al. (2008). Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences, 105(11), 4283–4288.
Kadiyska, T. K., Konstantinova, D. V., Atanasov, V. R., Kremensky, I. M., & Mitev, V. I. (2007). Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for hereditary nonpolyposis colorectal cancer. Cancer Detection and Prevention, 31(3), 254–256.PubMed
Kastrinos, F., Mukherjee, B., Tayob, N., Wang, F., Sparr, J., Raymond, V. M., et al. (2009). Risk of pancreatic cancer in families with Lynch syndrome. JAMA, 302(16), 1790–1795.PubMed
Kawaguchi, M., Yanokura, M., Banno, K., Kobayashi, Y., Kuwabara, Y., Kobayashi, M., et al. (2009). Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. International Journal of Oncology, 34(6), 1541–1547.PubMed
Kim, H. S., Lee, B. L., Woo, D. K., Bae, S. I., & Kim, W. H. (2001). Assessment of markers for the identification of microsatellite instability phenotype in gastric neoplasms. Cancer Letters, 164, 61–68.PubMed
Koornstra, J. J., Mourits, M. J. E., Sijmons, R. H., Leliveld, A. M., Hollema, H., & Kleibeuker, J. H. (2009). Management of extracolonic tumours in patients with Lynch syndrome. The Lancet Oncology, 10(4), 400–408.PubMed
Kovacs, M. E., Papp, J., Szentirmay, Z., Otto, S., & Olah, E. (2009). Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Human Mutation, 30(2), 197–203.PubMed
Kuismanen, S. A., Moisio, A. L., Schweizer, P., Truninger, K., Salovaara, R., Arola, J., et al. (2002). Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. The American Journal of Pathology, 160(6), 1953–1958.PubMed
Ligtenberg, M. J. L., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., et al. (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nature Genetics, 41(1), 112–117.PubMed
Lindor, N. M., Burgart, L. J., Leontovich, O., Goldberg, R. M., Cunningham, J. M., Sargent, D. J., et al. (2002). Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. Journal of Clinical Oncology, 20(4), 1043–1048.PubMed
Lindor, N. M., Rabe, K., Petersen, G. M., Haile, R., Casey, G., Baron, J., et al. (2005). Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA, 293(16), 1979–1985.PubMed
Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., et al. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA, 296(12), 1507–1517.PubMed
Liu, S. R., Zhao, B., Wang, Z. J., Wan, Y. L., & Huang, Y. T. (2004). Clinical features and mismatch repair gene mutation screening in Chinese patients with hereditary nonpolyposis colorectal carcinoma. World Journal of Gastroenterology, 10(18), 2647–2651.PubMed
Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., et al. (2007). Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer, 6(3), 301–310.PubMed
Loukola, A., Salovaara, R., Kristo, P., Moisio, A. L., Kaariainen, H., Ahtola, H., et al. (1999). Microsatellite instability in adenomas as a marker for hereditary nonpolyposis colorectal cancer. The American Journal of Pathology, 155(6), 1849–1853.PubMed
Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et al. (2007). Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. Journal of Clinical Oncology, 25(33), 5158–5164.PubMed
Lynch, H. T., & Smyrk, T. (1996). Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer, 78(6), 1149–1167.PubMed
Lynch, H. T., Harris, R. E., Lynch, P. M., Guirgis, H. A., Lynch, J. F., & Bardawil, W. A. (1977). Role of heredity in multiple primary cancer. Cancer, 40(4 Suppl), 1849–1854.PubMed
Lynch, H. T., Coronel, S. M., Okimoto, R., Hampel, H., Sweet, K., Lynch, J. F., et al. (2004). A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA, 291(6), 718–724.PubMed
Maeda, T., Cannom, R. R., Beart, R. W., Jr., & Etzioni, D. A. (2010). Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 28(7), 1175–1180.PubMed
Mecklin, J. P., & Jarvinen, H. J. (1986). Clinical features of colorectal carcinoma in cancer family syndrome. Diseases of the Colon and Rectum, 29(3), 160–164.PubMed
Miyakura, Y., Sugano, K., Akasu, T., Yoshida, T., Maekawa, M., Saitoh, S., et al. (2004). Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clinical Gastroenterology and Hepatology, 2(2), 147–156.PubMed
Muller, W., Burgart, L. J., Krause-Paulus, R., Thibodeau, S. N., Almeida, M., Edmonston, T. B., et al. (2001). The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)–results of an international collaborative study. Fam Cancer, 1(2), 87–92.PubMed
Muller, A., Giuffre, G., Edmonston, T. B., Mathiak, M., Roggendorf, B., Heinmoller, E., et al. (2004). Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. The Journal of Molecular Diagnostics, 6(4), 308–315.PubMed
Muller, A., Beckmann, C., Westphal, G., Bocker Edmonston, T., Friedrichs, N., Dietmaier, W., et al. (2006). Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study. International Journal of Colorectal Disease, 21(7), 632–641.PubMed
Myrhøj, T., Andersen, M. B., & Bernstein, I. (2008). Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Familial Cancer, 7(4), 303–307.PubMed
Nakagawa, H., Lockman, J. C., Frankel, W. L., Hampel, H., Steenblock, K., Burgart, L. J., et al. (2004). Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Research, 64(14), 4721–4727.PubMed
Niessen, R. C., Kleibeuker, J. H., Westers, H., Jager, P. O., Rozeveld, D., Bos, K. K., et al. (2009). PMS2 involvement in patients suspected of Lynch syndrome. Genes, Chromosomes & Cancer, 48(4), 322–329.
Nystrom-Lahti, M., Wu, Y., Moisio, A. L., Hofstra, R. M., Osinga, J., Mecklin, J. P., et al. (1996). DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Human Molecular Genetics, 5(6), 763–769.PubMed
Offit, K. (2004). MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie. Journal of Clinical Oncology, 22(22), 4449–4451.PubMed
Ollila, S., Fitzpatrick, R., Sarantaus, L., Kariola, R., Ambus, I., Velsher, L., et al. (2006). The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC. International Journal of Oncology, 28(1), 149–153.PubMed
Orta, L., Klimstra, D. S., Qin, J., Mecca, P., Tang, L. H., Busam, K. J., et al. (2009). Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient’s age or other clinical characteristics. The American Journal of Surgical Pathology, 33(6), 934–944.PubMed
Pal, T., Permuth-Way, J., Kumar, A., & Sellers, T. A. (2008). Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clinical Cancer Research, 14(21), 6847–6854.PubMed
Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42–65.PubMed
Park, Y. J., Shin, K. H., & Park, J. G. (2000). Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clinical Cancer Research, 6(8), 2994–2998.PubMed
Peltomaki, P., & Vasen, H. (2004). Mutations associated with HNPCC predisposition—Update of ICG-HNPCC/INSiGHT mutation database. Disease Markers, 20(4–5), 269–276.PubMed
Plaschke, J., Engel, C., Kruger, S., Holinski-Feder, E., Pagenstecher, C., Mangold, E., et al. (2004). Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. Journal of Clinical Oncology, 22(22), 4486–4494.PubMed
Ponti, G., Losi, L., Pedroni, M., Lucci-Cordisco, E., Di Gregorio, C., Pellacani, G., et al. (2006). Value of MLH1 and MSH2 Mutations in the Appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. Journal of Investigative Dermatology, 126(10), 2302–2307.PubMed
Popat, S., Hubner, R., & Houlston, R. S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of Clinical Oncology, 23(3), 609–618.PubMed
Rahner, N., Hoefler, G., Hogenauer, C., Lackner, C., Steinke, V., Sengteller, M., et al. (2008). Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. American Journal of Medical Genetics. Part A, 146A(10), 1314–1319.PubMed
Renkonen-Sinisalo, L., Sipponen, P., Aarnio, M., Julkunen, R., Aaltonen, L. A., Sarna, S., et al. (2002). No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scandinavian Journal of Gastroenterology, 37(5), 574–577.PubMed
Renkonen-Sinisalo, L., Butzow, R., Leminen, A., Lehtovirta, P., Mecklin, J. P., & Jarvinen, H. J. (2007). Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. International Journal of Cancer, 120(4), 821–824.
Rijcken, F. E., Hollema, H., & Kleibeuker, J. H. (2002). Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut, 50(3), 382–386.PubMed
Rijcken, F. E., Mourits, M. J., Kleibeuker, J. H., Hollema, H., & van der Zee, A. G. (2003). Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecologic Oncology, 91(1), 74–80.PubMed
Rodriguez-Bigas, M. A., Boland, C. R., Hamilton, S. R., Henson, D. E., Jass, J. R., Khan, P. M., et al. (1997). A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. Journal of the National Cancer Institute, 89(23), 1758–1762.PubMed
Roupret, M., Catto, J., Coulet, F., Azzouzi, A. R., Amira, N., Karmouni, T., et al. (2004). Micorsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. Journal of Medical Genetics, 41, e91.PubMed
Ruszkiewicz, A., Bennett, G., Moore, J., Manavis, J., Rudzki, B., Shen, L., et al. (2002). Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology, 34(6), 541–547.PubMed
Sankila, R., Aaltonen, L. A., Jarvinen, H. J., & Mecklin, J. P. (1996). Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology, 110(3), 682–687.PubMed
Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et al. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine, 354(3), 261–269.PubMed
Senter, L., Clendenning, M., Sotamaa, K., Hampel, H., Green, J., Potter, J. D., et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419–428.PubMed
Simpson, A. J. G., Caballero, O. L., & Pena, S. D. J. (2001). Microsatellite instability as a tool for the classification of gastric cancer. Trends in Molecular Medicine, 7(2), 76–80.PubMed
Singer, G., Kallinowski, T., Hartmann, A., Dietmaier, W., Wild, P. J., Schraml, P., et al. (2004). Different types of microsatellite instability in ovarian carcinoma. International Journal of Cancer, 112(4), 643–646.
Singh, R. S., Grayson, W., Redston, M., Diwan, A. H., Warneke, C. L., McKee, P. H., et al. (2008). Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. The American Journal of Surgical Pathology, 32(6), 936–942.PubMed
South, C. D., Hampel, H., Comeras, I., Westman, J. A., Frankel, W. L., & de la Chapelle, A. (2008). The frequency of Muir-Torre syndrome among Lynch syndrome families. Journal of the National Cancer Institute, 100(4), 277–281.PubMed
South, C. D., Yearsley, M., Martin, E., Arnold, M., Frankel, W., & Hampel, H. (2009). Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genetics in Medicine, 11(11), 812–817.PubMed
Stoffel, E. M., & Syngal, S. (2005). Adenomas in young patients: what is the optimal evaluation? The American Journal of Gastroenterology, 100(5), 1150–1153.PubMed
Stoffel, E., Mukherjee, B., Raymond, V. M., Tayob, N., Kastrinos, F., Sparr, J., et al. (2009). Calculation of risk of colorectal and endometrial cancer among patients with lynch syndrome. Gastroenterology, 137(5), 1621–1627.PubMed
Suter, C. M., Martin, D. I., & Ward, R. L. (2004). Germline epimutation of MLH1 in individuals with multiple cancers. Nature Genetics, 36(5), 497–501.PubMed
Syngal, S., Fox, E. A., Eng, C., Kolodner, R. D., & Garber, J. E. (2000). Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. Journal of Medical Genetics, 37(9), 641–645.PubMed
Tan, T. Y., Orme, L. M., Lynch, E., Croxford, M. A., Dow, C., Dewan, P. A., et al. (2008). Biallelic PMS2 mutations and a distinctive childhood cancer syndrome. Journal of Pediatric Hematology/Oncology, 30(3), 254–257.PubMed
The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987a). Combination oral contraceptive use and the risk of endometrial cancer. JAMA, 257(6), 796–800.
The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987b). The reduction in risk of ovarian cancer associated with oral-contraceptive use. The New England Journal of Medicine, 316(11), 650–655.
The NCCN Clinical Practice Guidelines in Oncology™ Colorectal Cancer Screening (Version I. 2010). © 2009 National Comprehensive Cancer Network, Inc. Available at: http://​www.​nccn.​org. Accessed January 19, 2010. To view the most recent and complete version of the NCCN Guidelines, go online to http://​www.​nccn.​org.
Truninger, K., Menigatti, M., Luz, J., Russell, A., Haider, R., Gebbers, J.-O., et al. (2005). Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology, 128(5), 1160–1171.PubMed
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268.PubMed
van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J., Witjes, J. A., Hulsbergen-van de Kaa, C. A., Bodmer, D., et al. (2010). Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of Medical Genetics, 47(7), 464–470.PubMed
Vasen, H. F., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Diseases of the Colon and Rectum, 34(5), 424–425.PubMed
Vasen, H. F., Watson, P., Mecklin, J. P., Jass, J. R., Green, J. S., Nomizu, T., et al. (1994). The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Research, 14(4B), 1675–1678.PubMed
Vasen, H. F., Nagengast, F. M., & Khan, P. M. (1995). Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet, 345(8958), 1183–1184.PubMed
Vasen, H. F., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453–1456.PubMed
Vasen, H. F., Moslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., et al. (2007). Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of Medical Genetics, 44(6), 353–362.PubMed
Velayos, F. S., Allen, B. A., Conrad, P. G., Gum, J., Jr., Kakar, S., Chung, D. C., et al. (2005). Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. The American Journal of Gastroenterology, 100(5), 1143–1149.PubMed
Wagner, A., Barrows, A., Wijnen, J. T., van der Klift, H., Franken, P. F., Verkuijlen, P., et al. (2003). Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. American Journal of Human Genetics, 72(5), 1088–1100.PubMed
Wang, L., Cunningham, J. M., Winters, J. L., Guenther, J. C., French, A. J., Boardman, L. A., et al. (2003). BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Research, 63(17), 5209–5212.PubMed
Watson, P., Vasen, H. F., Mecklin, J. P., Bernstein, I., Aarnio, M., Jarvinen, H. J., et al. (2008). The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. International Journal of Cancer, 123(2), 444–449.
Whelan, A. J., Babb, S., Mutch, D. G., Rader, J., Herzog, T. J., Todd, C., et al. (2002). MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. International Journal of Cancer, 99(5), 697–704.
Wijnen, J., van der Klift, H., Vasen, H., Khan, P. M., Menko, F., Tops, C., et al. (1998a). MSH2 genomic deletions are a frequent cause of HNPCC. Nature Genetics, 20(4), 326–328.PubMed
Wijnen, J. T., Vasen, H. F., Khan, P. M., Zwinderman, A. H., van der Klift, H., Mulder, A., et al. (1998b). Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. The New England Journal of Medicine, 339(8), 511–518.PubMed
Wijnen, J., de Leeuw, W., Vasen, H., van der Klift, H., Moller, P., Stormorken, A., et al. (1999). Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Genetics, 23(2), 142–144.PubMed
Winawer, S. J., Zauber, A. G., Ho, M. N., O’Brien, M. J., Gottlieb, L. S., Sternberg, S. S., et al. (1993). Prevention of colorectal cancer by colonoscopic polypectomy. NEJM, 329(27), 1977–1981.PubMed
Zighelboim, I., Powell, M., Babb, S., Whelan, A., Schmidt, A., Clendenning, M., et al. (2009). Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 8(4), 501–504.PubMed
Metadata
Title
Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review
Authors
Scott M. Weissman
Cecelia Bellcross
Christina Chimera Bittner
Mary E. Freivogel
Joy Larsen Haidle
Pardeep Kaurah
Anna Leininger
Selvi Palaniappan
Kelle Steenblock
Thuy M. Vu
Molly S. Daniels
Publication date
01-02-2011
Publisher
Springer US
Published in
Journal of Genetic Counseling / Issue 1/2011
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-010-9325-x

Other articles of this Issue 1/2011

Journal of Genetic Counseling 1/2011 Go to the issue

Original Research

Communication of Genetic Risk Information to Daughters in Families with Fragile X Syndrome: The Parent’s Perspective

Original Research

More Appreciation of Life or Regretting the Test? Experiences of Living as a Mutation Carrier of Huntington’s Disease

Original Research

The Development of a Methodology for Examining the Process of Family Communication of Genetic Test Results

Letter to the Editor

Sex Testing or Gender Verification: Is There a Difference and Does it Matter?

Original Research

Can We Make Assumptions About the Psychosocial Impact of Living as a Carrier, Based on Studies Assessing the Effects of Carrier Testing?

Original Research

Prevalence of Genetic Testing in CHARGE Syndrome